GTCpFE

GTCpFE inhibits IKKα/β in the NF-κB pathway with anti-inflammatory activities and blocks p65 nuclear entry, which consists of Dimethyl fumarate (DMF) linked to Aspirin (ASA) (HY-14654). GTCpFE exhibits selective anti-cancer stem-like cell (CSC) activity by reducing mammosphere growth and the CD44+ CD24- immunophenotype. GTCpFE inhibits breast cancer stem cells, an important NFκB- and PGE2-dependent phenotype in aggressive cancers[1][2].

Product Specifications

CAS Number

1588866-45-8

UNSPSC

12352005

Target

IKK; NF-κB

Type

Reference compound

Related Pathways

NF-κB

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/gtcpfe.html

Smiles

O=C(OC1=CC=C(COC(/C=C/C(OCC)=O)=O)C=C1)C2=C(OC(C)=O)C=CC=C2

Molecular Formula

C22H20O8

Molecular Weight

412.39

References & Citations

[1]Kastrati I, et al. Design and synthesis of hybrid drugs to target inflammatory pathways in breast cancer[J]. Cancer Research, 2015, 75 (15_Supplement) : 4497-4497.|[2]Kastrati I, et al. A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties. BMC Cancer. 2015 Nov 4;15:845.